产品名称
(±)-磺吡酮, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
SMILES string
O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4
InChI key
MBGGBVCUIVRRBF-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
sulfinpyrazone
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... SLC22A12(116085)
正在寻找类似产品? 访问 产品对比指南
Application
Sulfinpyrazone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
E H Margulies et al.
Drugs, 20(3), 179-197 (1980-09-01)
Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent. It is active in man following oral administration and has been reported to be effective in
Sulfinpyrazone: relationship between dose, kinetics, plasma concentrations and biological effects.
M R Buchanan
Thrombosis research. Supplement, 4, 89-92 (1983-01-01)
Ashley M Laughney et al.
Science translational medicine, 6(261), 261ra152-261ra152 (2014-11-08)
Eribulin mesylate was developed as a potent microtubule-targeting cytotoxic agent to treat taxane-resistant cancers, but recent clinical trials have shown that it eventually fails in many patient subpopulations for unclear reasons. To investigate its resistance mechanisms, we developed a fluorescent
Uricosuric drugs, with special reference to probenecid and sulfinpyrazone.
A B Gutman
Advances in pharmacology, 4, 91-142 (1966-01-01)
Andrew C Kotze et al.
Antimicrobial agents and chemotherapy, 58(12), 7475-7483 (2014-10-08)
We used an enzyme induction approach to study the role of detoxification enzymes in the interaction of the anthelmintic compound naphthalophos with Haemonchus contortus larvae. Larvae were treated with the barbiturate phenobarbital, which is known to induce the activity of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持